Mabpharm Ltd
02181
Company Profile
Business description
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
Contact
Lujia Road East, Koutai Road West
Block G79, China Medical City
Taizhou225300
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
315
Stocks News & Analysis
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
stocks
Bookworm: Is this the secret to exceptional long-term returns?
Acceptance may be an investor’s best friend.
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,934.30 | 45.10 | -0.50% |
CAC 40 | 7,834.58 | 16.30 | 0.21% |
DAX 40 | 24,217.50 | 78.43 | -0.32% |
Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
FTSE 100 | 9,120.31 | 18.06 | -0.20% |
HKSE | 25,388.35 | 278.83 | -1.09% |
NASDAQ | 21,108.32 | 50.36 | 0.24% |
Nikkei 225 | 41,456.23 | 370.11 | -0.88% |
NZX 50 Index | 12,853.46 | 48.33 | 0.38% |
S&P 500 | 6,388.64 | 25.29 | 0.40% |
S&P/ASX 200 | 8,666.90 | 42.50 | -0.49% |
SSE Composite Index | 3,593.66 | 12.07 | -0.33% |